海外层面，北美巨头26年开年密集推进AI+医疗实质性产品和功能落地 1月8日，OpenAI重磅推出了ChatGPT Health，为客户提供健康咨询服务，每周超2.3亿人咨询健康问 题；1月12日，英伟达与礼来宣布将在五年内斥资10亿美元在旧金山湾区建立一个新的联合研究实验 室，以加速AI药物研发进程；1月12日，Anthropic宣布推出医疗保健和生命科学服务，使其Claude人工 智能平台的用户能够共享对其健康记录的访问权限，以便更好地了解用户的医疗信息；1月14日， OpenAI宣布1亿美元收购仅4名员工的线上医疗数据整合商Torch。 智通财经APP获悉，中邮证券发布研报称，全球药物研发外包服务市场规模将由2023年的1512亿美元进 一步增至2030年的3632亿美元，CAGR为13.3%。AI已成为新药物发现的"加速引擎"，通过预测结合 能、溶解性、毒性等关键参数，AI可以在虚拟空间中高速筛选、优化甚至从头设计出具有潜力的候选 分子或新材料，有望缩短药物发现时间。展望2026年，以晶泰、TEMPUS为代表的AI+制药赛道领军均 有望实现EBITDA首次转正，产业即将迎来估值重构期。 中邮证券主要观 ...

Core Viewpoint - The company is set to engage in daily related transactions with its affiliates for the year 2025, which are deemed necessary for normal business operations and will not harm the interests of the company or its shareholders [9][10]. Summary by Sections Related Party Transactions - The company has disclosed its related party transactions, including expected amounts and categories, with specific affiliates such as Beijing Bai'ao Pharmaceutical Co., Ltd. and Jiangsu Yong'an Pharmaceutical Co., Ltd. [1][3][4][5][6]. - The expected transaction amounts are calculated based on the company's projected expenditures or revenues for similar business activities in 2024 [1]. Performance and Compliance - The affiliates involved in the transactions have good credit and financial conditions, ensuring their ability to fulfill contractual obligations without creating bad debts for the company [2]. - The company will sign contracts with related parties for the expected daily transactions in 2025, ensuring legal protection for performance [2][8]. Pricing Policy - The pricing policy for related party transactions is based on fair and just principles, using market prices as a reference. Agreements are made voluntarily and equitably [7]. Purpose and Impact - The anticipated related transactions are essential for the company's operational needs, aimed at consolidating market presence, enhancing operational capabilities, and promoting profit growth. The transactions are structured to avoid dependency on related parties [9][10]. Approval Process - The expected related party transactions for 2025 have been approved by the company's board and will be submitted for shareholder approval [10][21]. Financial Indicators - The company reported a significant increase in R&D investment, amounting to 171.94 million yuan in 2024, representing a 39.02% increase from 2023, with R&D expenses accounting for 15.94% of total revenue [46]. Competitive Advantages - The company has established a comprehensive drug development service model, enhancing its ability to meet diverse client needs and improve the success rate of drug development [38][39]. - The company has developed specialized core technology clusters in high-difficulty research areas, providing a competitive edge in the market [39][40]. Client Relationships - The company has built strong client relationships through integrated drug development services, serving approximately 1,000 pharmaceutical enterprises, which enhances customer loyalty and supports future business growth [45]. Regulatory Compliance - The company has adhered to relevant laws and regulations regarding fundraising and the use of raised funds, ensuring compliance and protecting shareholder interests [49]. Management Changes - The company has undergone changes in its board of directors, including the resignation of an independent director and the nomination of a new candidate, ensuring compliance with governance requirements [51][52].